Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hormone Replacement in Menopausal Women With Epilepsy

This study has been completed.
Sponsor:
Information provided by:
National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier:
NCT00027209
First received: November 28, 2001
Last updated: May 12, 2006
Last verified: November 2005
  Purpose

The goal of this study is to evaluate the effect of synthetic hormone replacement therapy on anti-seizure medication levels, menopausal symptom relief, and seizure frequency and safety in menopausal women with epilepsy.


Condition Intervention Phase
Menopause
Epilepsy
Drug: prempro
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Institute of Neurological Disorders and Stroke (NINDS):

Estimated Enrollment: 125
Detailed Description:

This study will help to answer questions regarding the use of hormone replacement therapy that women with epilepsy face as they reach menopause. The total duration of the study is 6 months and involves 7 visits to the doctor. The purposes of the study are to discover if and how menopause and treatments for the symptoms of menopause change epilepsy in women, to determine which if any factors present before and/or during menopause may predict the influence of menopause on a woman's seizure disorder, and to find any possible interactions between hormone replacement therapy and anti-seizure medication in order to find the optimal dose of hormone replacement therapy for women with epilepsy.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have a diagnosis of partial epilepsy which has predated the onset of menopause.
  • Subjects must have between 0-10 seizures of any type per month.
  • Subjects must have had an EEG consistent with a partial epilepsy diagnosis, showing a focal abnormality.
  • Subjects must have had an imaging study of the brain since the diagnosis of epilepsy.
  • Subjects must be 1 year menopausal (without their menstrual periods), but within 5 years of their last menstrual period.
  • Subjects must be medically cleared by their primary care physician to take HRT.
  • Subjects must have had a normal PAP smear within the past 9 months.
  • Subjects must have had a mammogram without lesions suspicious for malignancy within the past 9 months.
  • Subjects or their caregivers must be able to keep an accurate seizure diary.
  • Subjects must be stable on their current AEDs for >1 month.
  • Subjects must have not used HRT during the 3 months prior to enrollment.

Exclusion Criteria:

  • Subjects with a history of breast, uterine or ovarian cancer.
  • Subjects with a treatable or reversible cause of recurrent seizures (metabolic, neoplastic, toxic or infectious causes).
  • Subjects with a history of deep vein thrombosis, arterial thrombosis, pulmonary embolus, blood clotting disorders, or stroke.
  • Subjects with elevated liver function test more than two time normal.
  • Subjects with 3 first degree family members who have a history of breast cancer.
  • Subjects with 1 first degree family member with a history of bilateral breast cancer.
  • Subjects with a history of complicated migraine headaches.
  • Subjects with a history of unexplained vaginal bleeding.
  • Subjects with a history of familial hyperlipoproteinemia.
  • Subjects with a history of myocardial infarction in the past 6 months.
  • Subjects with diabetes mellitus with vascular disease.
  • Subjects with untreated hypertension (>145/95 on 3 occasions).
  • Subjects with a history of using an experimental drug or device in the past 30 days.
  • Subjects with severe chronic and/or progressive medical illnesses.
  • Subjects with active drug and alcohol abuse.
  • Subjects with a history of discontinuation of Prempro in the past due to side effects.
  • Subjects who state that they cannot tolerate 6 more months without relief of menopausal symptoms.
  • Subjects who plan to change or anticipate a change in their antiseizure treatment in the next 6 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00027209

Locations
United States, New York
New York Presbyterian Hospital-Weill Medical College of Cornell University, Comprehensive Epilepsy Center
New York, New York, United States, 10021
Sponsors and Collaborators
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00027209     History of Changes
Other Study ID Numbers: R01NS38473
Study First Received: November 28, 2001
Last Updated: May 12, 2006
Health Authority: United States: Federal Government

Keywords provided by National Institute of Neurological Disorders and Stroke (NINDS):
seizures
epilepsy
menopause

Additional relevant MeSH terms:
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on November 25, 2014